RevMed gets FDA approval for pancreatic cancer drug Daraxonrasib, hailed as 'historic' breakthrough

Published Aug 28, 02:58 PM UTC

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Source reporting is collected, normalized, translated or condensed automatically when needed.
Page status: Automatically published source-backed update

How automation and AI are used · Report a correction or rights issue

The FDA has approved a new drug, Daraxonrasib, for the treatment of pancreatic cancer, a milestone described as 'historic' and 'exceptional' by researchers and media. Revolution Medicines (RevMed) is preparing for the commercial launch of the drug, which is poised to transform treatment for the deadly disease. However, questions remain regarding the drug's real-world impact, access, and integration into existing treatment protocols. The approval has been covered by major outlets including the Wall Street Journal, New York Times, Bloomberg, and CBS News, highlighting its significance as a breakthrough in a field with few therapeutic options.

Source report

Revolution Medicines Prepares for 'Historic' Pancreatic Cancer Launch Amid Lingering Questions

Fierce Pharma reports that as Revolution Medicines (RevMed) prepares for what it calls a "historic" launch of a pancreatic cancer treatment, questions remain on the ground.

FDA Approves New Drug for Pancreatic Cancer in Milestone for Deadly Disease

The Wall Street Journal covers the FDA's approval of a drug for pancreatic cancer, marking a significant milestone in the treatment of this deadly disease.

FDA Approves Daraxonrasib, Poised to Transform Pancreatic Cancer Treatment

The New York Times reports that the FDA has approved the drug Daraxonrasib, which experts say is poised to transform the treatment of pancreatic cancer.

Pancreatic Cancer Drug Approval Called 'Exceptional Moment' by Boston Researcher

CBS News quotes a Boston researcher who describes the FDA's approval of a pancreatic cancer drug as an "exceptional moment."

Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment

Bloomberg highlights that a breakthrough pancreatic cancer drug signals a new era in treatment for the disease.

Source

Part of this Story

FDA Approves Revolution Medicines' Pancreatic Cancer Pill Rasonque, Doubling Survival

See the full Story: all sources and camp coverage

People and interests

FDA